Stay updated with breaking news from Visual Index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology - read this article along with other careers information, tips and advice on BioSpace
Rare dermatologic disease R&D is growing at a much faster rate than other fields in dermatology. Even before the data readout from our Phase 2b...
Timber Pharmaceuticals Announces Late-Breaking Presentation at the American Academy of Dermatology 2022 Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
TMB-001 is a topical isotretinoin formulation that uses a patented 'IPEG' technology isotretinoin delivery system.
If you are familiar with rare diseases, you know there are unique challenges associated with conducting clinical trials to evaluate potential new...